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N-O-D-00599
Lynch syndrome (LS) is an inherited condition of defective DNA mismatch repair (MMR). LS is caused by
autosomal dominant heterozygous germline mutations in one of four MMR genes: mutL homologue 1
(MLH1), mutS homologue 2 (MSH2), mutS homologue 6 (MSH6) and postmeiotic segregation
increased 2 (PMS2). Individuals with LS are primarily predisposed to gastrointestinal and endometrial
but also other cancers including astrocytomas and oligodendrogliomas (although the literature lacks
documented reports of 1p19q co-deletion specifically in this cohort) 1, 2.
The MMR system repairs base-pair mismatches that are generated by errors in base pairing during DNA
replication 3. Patients with LS have a germline mutation in one allele of a MMR gene but require a
somatic inactivation of the remaining wild-type allele in order for cancers to develop 4. Constitutional
mismatch repair deficiency syndrome, on the other hand, results from biallelic germline mutations in
one of the four MMR genes 5. Ultimately, biallelic inactivation of MMR genes causes an increased
mutation rate leading to a hypermutator phenotype which is characteristic of MMR deficient tumors. In
addition, polymorphisms accumulate within the microsatellite repeat regions due to DNA polymerase
slippage events leading to microsatellite instability (MSI).
Temozolomide (TMZ) - an alkylating agent - is a standard option in the treatment of gliomas. TMZ
induces DNA damage by methylating the N7 and O6 positions of guanine and the N3 position of adenine.
O6 DNA-methylation is highly mutagenic and induces a futile mismatch repair cycle generating lethal
double-strand breaks leading to checkpoint activation and apoptosis 4.
Given the dependence on functional mismatch repair for the efficacy of TMZ and other alkylating agents
6
, MMR-deficient cells are inherently more resistant to their cytotoxic effects and may survive at the cost
of extensive mutagenesis 7, 8. Recently, glioma patient-derived cell lines with CRISPR–Cas9 mediated
knockout of MSH2, MSH6, MLH1 or PMS2 showed resistance to temozolomide, a monofunctional
alkylator but not to lomustine (CCNU), a bifunctional alkylating agent 9. Similarly, loss of MMR function
has been observed in recurrent glioblastomas following treatment with TMZ primarily by inactivation of
MSH6 leading to treatment resistance 10, 11. The role of MMR in the cytotoxicity of ionizing radiation is
less well understood and may depend on the dose of radiation 6, 12. However, risks should be weighed
against benefits from treatment in patients with LS given the theoretical risk of secondary malignancies
13
.
The base excision repair (BER) pathway is important in the repair of DNA damage at the N3-adenine and
N7-guanine base lesions. The DNA repair enzyme, poly (ADP-ribose) polymerase (PARP) has an important
role in the proper repair of single-strand DNA breaks that are generated during BER 14. PARP inhibitors
have been tested for their ability to enhance the activity of TMZ. The effect was most pronounced in
MMR-deficient cells, which are generally resistant to the effects of temozolomide as discussed above 7.
In fact, recent data suggests resensitization of MSH6-inactivated, MMR-deficient glioblastoma cells with
combination treatment of PARP inhibitors plus temozolomide 15.
While LS in not routinely screened for in clinical practice, strong family history of relevant cancers,
personal history of more than one cancer, or an incidental finding of one of the LS mutations when
sequencing gliomas suggest the need for referral to genetic counseling. The above data raises concerns
about using the standard of care regimen including TMZ when treating patients with LS and gliomas.
Rather, the use of CCNU or a combination of TMZ plus PARP inhibition have a stronger biological
rationale. The concern also applies to procarbazine when using procarbazine, CCNU and vincristine (the
PCV regimen) for oligodendrogliomas 14. Furthermore, the use of immune checkpoint inhibitors is now
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approved by the FDA for solid tumors with MSI or MMR deficiency and is an option for LS glioma
patients. However, more research is needed as it was interestingly noted that MSI may not be always
present in MMR-deficient gliomas 9 and initial case series suggest lack of efficacy of immunotherapy in
recurrent MMR-deficient gliomas 9, 16. A clinical trial is ongoing NCT02359565.
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